PMID- 17965976 OWN - NLM STAT- MEDLINE DCOM- 20080530 LR - 20220309 IS - 0033-3158 (Print) IS - 1432-2072 (Electronic) IS - 0033-3158 (Linking) VI - 196 IP - 3 DP - 2008 Feb TI - CRF(1) receptor antagonists attenuate escalated cocaine self-administration in rats. PG - 473-82 AB - RATIONALE: Previous work suggests a role for stress-related corticotropin-releasing factor (CRF) systems in cocaine dependence. However, the involvement of activation of CRF(1) receptors in rats self-administering cocaine with extended access is unknown. OBJECTIVE: The current study examined whether CRF(1) receptor antagonist administration alters cocaine self-administration in animals given extended access. MATERIALS AND METHODS: Wistar rats (n = 32) acquired cocaine self-administration (0.66 mg/kg per infusion) in 1 h sessions for up to 11 days. Rats then were assigned to receive either daily short (1 h, ShA) or long (6 h, LgA) access to cocaine self-administration (n = 7-9 per group). Following escalation of intake, animals received one of two selective CRF(1) antagonists: antalarmin (6.3-25 mg/kg, i.p.) or N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-pyrazolo[1,5a]pyrimidin-7-amine (MPZP; 3.6-27.5 mg/kg, s.c.). RESULTS: By day 11 of the escalation period, LgA rats increased their cocaine intake, reaching an intake level of 15.1 mg/kg, compared to 11.1 mg/kg in ShA rats, during the first hour of sessions. Antalarmin reduced cocaine self-administration at the highest dose selectively in the LgA group but not the ShA group. MPZP reduced cocaine intake both in LgA and ShA rats. However, MPZP did so at a lower dose in LgA rats than in ShA rats. Within the LgA group, MPZP decreased cocaine intake in the first 10 min (loading phase) as well as in the latter session intake (maintenance phase). CONCLUSION: The data suggest that hypersensitivity of the CRF system occurs with extended access to cocaine self-administration and that this altered CRF system may contribute to the increased motivation to self-administer cocaine that develops during psychostimulant dependence. FAU - Specio, Sheila E AU - Specio SE AD - The Scripps Research Institute, La Jolla, CA 92037, USA. FAU - Wee, Sunmee AU - Wee S FAU - O'Dell, Laura E AU - O'Dell LE FAU - Boutrel, Benjamin AU - Boutrel B FAU - Zorrilla, Eric P AU - Zorrilla EP FAU - Koob, George F AU - Koob GF LA - eng GR - R01 DA004398/DA/NIDA NIH HHS/United States GR - R01 DA004398-21/DA/NIDA NIH HHS/United States GR - DA004398/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20071030 PL - Germany TA - Psychopharmacology (Berl) JT - Psychopharmacology JID - 7608025 RN - 0 (Dopamine Uptake Inhibitors) RN - 0 (N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-amine) RN - 0 (Pyrimidines) RN - 0 (Pyrroles) RN - 0 (Receptors, Corticotropin-Releasing Hormone) RN - 0 (antalarmin) RN - 5CLY6W2H1M (CRF receptor type 1) RN - I5Y540LHVR (Cocaine) SB - IM MH - Animals MH - *Behavior, Addictive MH - Cocaine/*administration & dosage MH - Dopamine Uptake Inhibitors/*administration & dosage MH - Dose-Response Relationship, Drug MH - Male MH - Pyrimidines/administration & dosage/pharmacology MH - Pyrroles/administration & dosage/pharmacology MH - Rats MH - Rats, Wistar MH - Receptors, Corticotropin-Releasing Hormone/*antagonists & inhibitors MH - Self Administration MH - Time Factors PMC - PMC2769571 MID - NIHMS140627 EDAT- 2007/10/30 09:00 MHDA- 2008/05/31 09:00 PMCR- 2009/10/28 CRDT- 2007/10/30 09:00 PHST- 2007/03/12 00:00 [received] PHST- 2007/10/09 00:00 [accepted] PHST- 2007/10/30 09:00 [pubmed] PHST- 2008/05/31 09:00 [medline] PHST- 2007/10/30 09:00 [entrez] PHST- 2009/10/28 00:00 [pmc-release] AID - 10.1007/s00213-007-0983-9 [doi] PST - ppublish SO - Psychopharmacology (Berl). 2008 Feb;196(3):473-82. doi: 10.1007/s00213-007-0983-9. Epub 2007 Oct 30.